Clinical Trial

Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Study acronym: ZENOBIA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-18; most recent amendment 2025-11-04.
Status change: Not Yet Recruiting → Recruiting 2024-12-09
Trial Details
NCT Number NCT06698250
Lead Sponsor Anwaar Saeed
Collaborators: Exelixis
Conditions Hepatocellular Carcinoma
Enrollment 40 participants
Start Date 2024-12-18
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-06